Zanamivir to prevent influenza [2] (multiple letters)

New England Journal of Medicine

Volumn 344, Issue 7, 2001, Pages 528-530

  Feder Jr , Henry M ^a   Van Der Wouden, Johannes C ^b   Van Bentveld, Reinout D W ^b   Bernsen, Roos M D ^b   Hayden, Frederick G ^c   Elliot, Michael J ^d  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY OF VIRGINIA   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PLACEBO; ZANAMIVIR; ANTIVIRUS AGENT; GUANIDINE DERIVATIVE; PYRAN DERIVATIVE; SIALIC ACID DERIVATIVE;

CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG COST; HUMAN; INFLUENZA; LETTER; PRIORITY JOURNAL; PROPHYLAXIS; VACCINATION; FAMILY; NOTE; COST BENEFIT ANALYSIS; ECONOMICS;

ANTIVIRAL AGENTS; FAMILY; GUANIDINES; HUMANS; INFLUENZA, HUMAN; PYRANS; SIALIC ACIDS; ZANAMIVIR; COST-BENEFIT ANALYSIS; INFLUENZA VACCINES;

EID: 0035864945     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200102153440714     Document Type: Letter

References (0)